The Type 2 Diabetes Mellitus therapeutics in major developed markets analysis report includes forecast to year 2021 for Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets of US, Canada, UK, France, Germany, Italy, Spain and Japan. The other important points covered in detail in the report are disease etiology and pathophysiology; treatment algorithms and treatment segments; key marketed drugs and therapies, detailed pipeline analysis, clinical trial results, promising pipeline molecules by pharmaceutical companies and important licensing and co-development deals.

1. Type 2 Diabetes Mellitus Treatment Market
Forecast to Year 2021 in Major Developed
Markets: Market growing a CAGR of 7.5% and
will reach $39 billion by 2021
Absolute Reports Monday, June 27th, 2016
Contact Profile
Absolute Reports
Absolute Reports is an upscale platform
to help key personnel in the business
world in planning and executing
visionary decisions based on facts and
figures derived from in depth market
research. The market analysis included
in the reports we resell takes into
account a multitude of market
dynamics and presents highly
congruous business intelligence. We are
one of the top report resellers in the
market, committed towards bestowing
an ingenious concoction of data
parameters to our buyers. Absolute
Reports aims to apprise the market
players of all levels with an accurate
and concise amalgamation of vital
market data which will facilitate their
dominance in the industry.
Ameya Pingaley
P: +1-408 520 9750
W: www.absolutereports.com
E: sales@absolutereports.com
The Type 2 Diabetes Mellitus therapeutics in major developed markets analysis
report includes complete forecast up to 2021 for Type 2 Diabetes Mellitus
Therapeutics in Major Developed Markets of US, Canada, UK, France, Germany,
Italy, Spain and Japan. The other important points covered in detail in the report
are disease etiology and pathophysiology; treatment algorithms and treatment
segments; key marketed drugs and therapies, detailed pipeline analysis, clinical
trial results, promising pipeline molecules by Major pharmaceutical companies
and important licensing and co-development deals.
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic
hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly
in the past several decades, particularly in line with obesity. This has been
attributed to a range of factors, including economic development, increasing
urbanization, aging populations, and changes in lifestyle patterns such as
reduced levels of physical activity and consumption of higher-calorie diets.
Browse detailed TOC, Tables, Figures, Charts and Companies mentioned in Type
2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 – Strong
Pipeline and Expanding Treatment Population to Encourage Robust Growth
Market Research
Report at-
http://www.absolutereports.com/type-2-diabetes-mellitus-therapeutics-in-major-
developed-markets-to-2021-strong-pipeline-and-expanding-t-
eatment-population-to-encourage-robust-growth-10070556
This has led to strong commercial interest in the development of T2DM
therapeutics. The current market is large and diverse, comprising several drug
classes, including generic and branded drugs. Owing to the range of therapeutic
options available, the treatment algorithm is complex. However, current
treatment regimens are often associated with limited long-term efficacy,
complex and inconvenient dosing regimens, and undesirable side effects such
as weight gain and hypoglycemia (low blood glucose levels).
Promising pipeline molecules by major pharmaceutical companies like Merck,
Novo Nordisk, Intarcia Therapeutics, Lexicon Pharmaceuticals, Eli Lilly and
Company, Isis Pharmaceuticals and Biospherics.net Incorporated have been
covered in the report.

2. Get 25% Discount on Corporate Licence of Type 2 Diabetes Mellitus
Therapeutics in Major Developed Markets to 2021 – Strong Pipeline and
Expanding Treatment Population to Encourage Robust Growth Market Research
Report at –http://www.absolutereports.com/enquiry/request-discount/10070556
Offer valid till 1st July 2016
Scope of the report:
– Metformin monotherapy will remain the first-line pharmacotherapy for T2DM.
– The emergence of several new drug classes over the past decade, namely the
Glucagon-Like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase 4 (DPP-
4) inhibitors, and Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors, has led
to considerable market growth.
– Which products lead these drug classes and what threats do they face from
the pipeline?
– How will the continued uptake of newer drug classes impact established drug
classes such as the sulfonylureas and thiazolidinediones?
– Leading insulin therapy Lantus (insulin glargine) recently lost patent
protection in most major markets.
– Will recently approved insulin therapies such as Tresiba (insulin degludec)
and Toujeo (insulin glargine) be able to capture a significant portion of Lantus’
market share?
– The pipeline is large and highly innovative, comprising a range of molecule
types and molecular targets.
– How do different molecule types and molecular targets compare in terms of
average failure rate, clinical trial duration, and clinical trial size?
– Which late-stage pipeline molecules show the most promise and how will they
impact the treatment algorithm over the forecast period?
– Which late-stage pipeline molecules are expected to generate the highest
revenues?
– Over the 2014–2021 forecast period, the global T2DM market is expected to
increase in value at a CAGR of 7.5% from $23.5 billion to $39.0 billion.
– How do prevalence, diagnosis, and treatment patterns vary in the eight major
markets?
– Which factors will drive market growth most significantly?
– Strategic consolidation activity in T2DM is considerable, with US-based
companies being key players.
– Do T2DM products tend to attract high levels of investment?
Request sample PDF of Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021 – Strong Pipeline and Expanding Treatment
Population to Encourage Robust Growth Market Research
Report at-http://www.absolutereports.com/enquiry/request-sample/10070556
How helpful is the report?

3. The report will help to:
– Understand the clinical context of the T2DM indication and the global burden
of the disease by considering epidemiology, symptoms, etiology,
pathophysiology, co-morbidities and complications, disease classification,
disease prognosis, and treatment options.
– Appreciate the current T2DM marketed products landscape, including the
dominant therapeutic strategies, products, and companies, and recognize gaps
within the market and areas of unmet need.
– Identify key pipeline trends in molecule type and molecular target.
– Recognize the late-stage pipeline molecules that have demonstrated strong
therapeutic potential in T2DM by examining clinical trial data and multi-scenario
product forecast projections.
– Consider market opportunities and potential risks by examining trends in
T2DM clinical trial size, duration, and failure rate by phase of development,
molecule type, and molecular target.
– Discern variances in treatment usage patterns, annual therapy costs, and
market growth projections for the US, Canada, the UK, France, Germany, Italy,
Spain, and Japan.
– Discover how strategic consolidations have shaped the current T2DM pipeline
and marketed products landscapes.
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business
world in strategizing and taking visionary decisions based on facts and figures
derived from in depth market research. We are one of the top report resellers in
the market, dedicated towards bringing you an ingenious concoction of data
parameters.
Contact–
Mr. Ameya Pingaley
Absolute Reports
+1-408 520 9750
Email – sales@absolutereports.com
www.absolutereports.com
File Library